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Abstract Two cytoplasmic forms of pyrimidine nucleotidase 
(PN-I and PN-II) have been purified from human erythrocytes 
to apparent homogeneity and partially characterized. They 
preferentially hydrolyse pyrimidine 5'-monophosphates and 
3'-monophosphates respectively. PN-I and PN-II operate as 
interconverting activities, capable of transferring the phosphate 
from the pyrimidine nucleoside monophosphate donor(s) to 
various nucleoside acceptors, including important drugs like 
3'-azido-3'-deoxy-thymidine (AZT), cytosine-ß-D-arabinofura-
noside (AraC) and 5-fluoro-2'-deoxy-uridine (5FdUrd), pyrimi-
dine analogues widely used in chemotherapy. Kinetic analysis 
showed linear behaviour for both PN-I and PN-II. PN-I 
phosphotransferase activity revealed higher affinity for oxy-
nucleosides with respect to deoxy-nucleosides, whereas the 
contrary seems to be true for PN-II. These results show for the 
first time that soluble pyrimidine nucleotidases are endowed with 
pyrimidine-specific phosphotransferase activity. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Two pyrimidine-specific nucleotidases (PN-I and PN-II; EC 
3.1.3.5), are present in the soluble fraction of human eryth-
rocytes [1,2]. Unlike nucleotidases from other sources, PN-I 
and PN-II are essentially inactive toward purine nucleotides. 
This unique substrate restriction appears to match with the 
needs of the red cell metabolism, which critically depends 
upon a limited reservoir of ATP, whose base cannot be syn-
thesized de novo in the erythrocyte. Since the components of 
adenine nucleotide pool, in erythrocytes, are in rapid equilib-
rium through the mediation of adenylate kinase, the presence 
of a nucleotidase acting on AMP and producing diffusible 
adenosine should impose their inexorable drain [3]. Indeed a 
purine-specific nucleotidase, shown to be present in yeast, is 
almost inactive toward adenylic nucleoside monophosphates. 
It is well established that hereditary deficiency of one of these 
enzymes (PN-I) results in non-spherocytic haemolytic anemia. 
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dine-5'-monophosphate; 5'-Ara-CMP, cytosine-ß-D-arabino-
furanoside-5'-monophosphate; 5'-FdUMP, 5-fluoro-deoxy-uridine-
5'-monophosphate; AZT, 3'-azido-3'-deoxy-thymidine; AraC, cyto-
sine-i?-D-arabinofuranoside; 5FdUrd, 5-fluoro-2'-deoxy-uridine; 
DTT, dithiothreitol; p-CMB, /)-chloromercuribenzoate; DTNB, 5,5'-
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Such a condition determines a marked erythrocyte accumula-
tion of pyrimidine nucleotides, detectable both by spectropho-
tometrically [1] and by a HPLC-based assay [4], and is accom-
panied by a distinctive basophilic stippling of erythrocytes 
upon Wright staining of blood smears [1]. Furthermore it 
has been shown [3,5,6] that affected patients, although defec-
tive in erythrocyte 5'-nucleotidase activity towards UMP, 
CMP and dCMP, conserved normal activity toward dUMP 
and dTMP. These findings were explained by the presence of 
PN-II activity [2,7]. Both enzymes have been purified to ap-
parent homogeneity in our laboratory [8,9]. The two nucleo-
tidase activities exhibited different enzymatic and molecular 
properties, supporting the hypothesis on the existence of 
two different genes coding for the two enzymatic proteins 
[7]. Additional interest on the study of the erythrocyte nucleo-
tide metabolism derives from the use of pyrimidine analogues 
encapsulated as non-diffusible monophosphates in autologous 
erythrocytes, which have been used as carriers and bioreactors 
for the conversion of encapsulated pyrimidine analogues into 
their diffusible and pharmacologically active form [10]. The 
same authors reported on the involvement of the erythrocyte 
dephosphorylating machinery in the conversion of 5'-FdUMP 
to diffusible 5FdUrd, a potent antineoplastic agent. Further-
more it has been shown that purine nucleoside analogues can 
be phosphorylated through the action of 5'-nucleotidases, en-
dowed with phosphotransferase activity [11]. This phosphor-
ylating activity has drawn the attention of several research 
groups because nucleotidase might represent an alternative 
route to phosphorylate nucleoside analogues, which are not 
substrate of known cellular nucleoside kinases [12-14]. Thus, 
the study of the properties of the cytoplasmic pyrimidme nu-
cleotidases, which may play both a catabolic and an intercon-
verting role, might be of help for the understanding of the 
metabolic function of these two enzymes and for their possible 
utilization for the targeted activation of pyrimidine analogues. 
Knowledge of such enzyme system involved in the metabolism 
of pyrimidine nucleosides is therefore important in designing 
new drugs and innovative therapeutic approaches. 
2. Material and methods 
2.1. Materials 
Nucleosides, nucleotides, imidazole, Tris were purchased from Sig-
ma (St. Louis, MN, USA). Potassium dihydrogen phosphate, DTT, 
EDTA and chromatography grade methanol were from Merck 
(Darmstadt, Germany). Other reagents were of analytical grade. 
2.2. Nucleotidase assay 
Nucleotidase activity was measured by HPLC-based assay. The 
standard reaction mixture contained: 50 niM Tris/HCl pH 7.5, 
1 mM MgCl2, 1 mM DTT, 1 mM substrate, and the appropriate 
amount of enzyme sample, in a final volume of 500 ul. Incubations 
were carried out at 37°C for 5-120 min. The reaction was stopped by 
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adding 100 ul of assay mixture to 50 ul of ice-cold 1.2 M HCIO4 in an 
Eppendorf tube. After 10 min at 0°C protein pellet was removed by 
1 min centrifugation on microfuge. 130 ul of supernatant were neu-
tralized by the addition of 35 ul of 1 M K2C03 and formed KCIO4 
was removed by centrifugation. An appropriate aliquot of the neu-
tralized supernatant was injected into a HPCL apparatus to evaluate 
the amount of produced nucleoside. The elution was performed by the 
isocratic separation described by Amici et al. [15]. The HPLC was 
equipped with a 20 mm X 4.6 mm I.D. C-18 guard column, 5 urn 
particle size, equilibrated and eluted with 100 mM potassium phos-
phate buffer, pH 6.0, at 2 ml/min flow rate. In an alternative assay 
procedure, the enzyme activity was tested by measuring the amount of 
phosphate released, according to the method described by Ames [16], 
which uses the ammonium molybdate-ascorbic acid complex. 
2.3. Phosphotransferase assay 
Phosphotransferase activity was measured by a HPLC-based assay 
of formed nucleoside monophosphate. The reaction mixture condi-
tions were the same of nucleotidase assay, with the addition of an 
appropriate amount of nucleoside acceptor during the incubation at 
37°C. An appropriate aliquot of the neutralized supernatant was in-
jected into a HPLC apparatus to evaluate the amount of produced 
nucleoside. The HPLC was equipped with a 250 mm X 4.6 mm I.D. C-
18 column, 5 um particle size, equilibrated with 100 mM potassium 
phosphate buffer pH 6.0 (buffer A) at a flow rate of 1.3 ml/min. The 
elution of nucleosides and nucleoside monophosphates of the mixture 
was achieved by the following gradient of methanol in buffer A; 9 min 
at no methanol, 6 min at up to 2.4% of methanol, 2.5 min at up to 9% 
of methanol and 2.5 min at up to 20% of methanol. The column was 
then flushed for 5 min at 20%> of methanol and equilibrated with 
buffer A for 5 min prior to the next run. Replicate determinations 
at different incubation times were used to calculate each enzymatic 
activity point. One unit of enzyme activity (U) is defined as the 
amount of enzyme producing 1 umol of phosphate, nucleoside or 
nucleoside monophosphate per minute under the standard assay con-
ditions. 
2.4. Purification procedures of PN-I and PN-II 
In order to obtain enzyme preparations of suitable purity for ki-
netic experiments, the purification scheme described earlier by us [9] 
was applied both for PN-I and PN-II. Outdated bank blood was used 
as enzyme source. The two activities copurified from lysate through 
Phenyl-Sepharose CL4B (step 1 to step 4) and separated by the hy-
droxyapatite chromatography (step 5), as reported in [9]. The enzymes 
were further purified by parallel identical procedures performed in a 
FPLC system, consisting of step 6 and step 7, described in [9]. The 
resulting preparations were subjected to SDS-PAGE [17] and gel fil-
tration chromatography to check for their homogeneity. 
2.5. Other procedures 
Protein concentration was determined as described by Bradford 
[18]. SDS-PAGE was conducted essentially as described by Schagger 
and von Jagow [17] with Tris/Tricine buffer, 10% acrylamide/bisacryl-
amide (T = 3%) running gel and 4% stacking gel. After electrophoresis, 
gel was Silver-stained [19]. Native Mr determination according to 
Andrews [20] was performed on a Superóse 12 HR 10/30 column 
(Pharmacia) connected to a FPLC system. The column was equili-
brated and eluted by using 50 mM Bis-Tris, pH 6.5, and 0.5 M 
NaCl, at a flow rate of 0.5 ml/min. The FPLC system (LKB) consisted 
of a single pump (model 2150), a gradient controller (model 2152), a 
fixed wavelength detector (Uvicord SD, model 2158) with a 279 nm 
filter, a two channel recorder (model 2210), and an automatic fraction 
collector (Elirac, model 2212). Samples were injected through a Valco 
valve equipped with a 1.0 ml loop. Isoelectric point determination was 
carried out by isoelectrofocusing on a 110 LKB 8100 ampholine col-
umn using a linear gradient of glycerol (0-65%) w/v) and 1% (w/v) pH 
3.5-10 ampholine carrier ampholytes. 
3. Results and discussion 
3.1. Enzyme purification 
The present study was carried out with apparently homoge-
neous preparations of PN-I and PN-II purified from human 
erythrocytes. The purification and the characterization of PN-
II have been previously reported by us [9]. PN-I and PN-II 
copurified until the fourth step of the purification procedure 
and then were separated during the hydroxyapatite chroma-
tography step. The PN-I fraction, obtained in the fourth step, 
was further purified by two FPLC steps identical to those 
described for PN-II, yielding a chromatographically and elec-
trophoretically homogeneous preparation. The purification of 
both enzymes is summarized in Table 1. 
3.2. Molecular and enzymatic properties 
The final preparation of PN-I had a specific activity of 28 
U/mg. SDS-PAGE showed a single band corresponding to a 
molecular weight of 34000 in agreement with the value of 
36 000 as determined by gel filtration, suggesting a monomeric 
structure for PN-I (not shown). The isoelectric point was 
found to be 5.1. The pH optimum was 7.5 and Mg2+ ions 
were required for PN-I catalytic activity. The presence of 
DTT was absolutely required during the early, common steps 
of the purification procedure since PN-I rapidly inactivates in 
the absence of sulphydryl protective reagents. Furthermore, 
the enzyme was totally inactivated by both p-CMB and 
DTNB at 1 mM concentration, thus suggesting the involve-
ment of cysteine residues in the enzymatic catalysis. The prop-
erties of PN-II have been previously reported in [9]. The spe-
cific activity of the preparation utilized in the present work 
was 73.9 U/mg. 
3.3. Substrate specificity 
PN-I preferentially hydrolyzed, in the order 5'-UMP, 5'-
CMP, 5'-AZTMP, 5'-Ara-CMP, 5'-dCMP, 5'-dTMP, 5'-
dUMP, while it was totally inactive toward purine nucleoside 
monophosphates, regardless the position of the phosphate 
moiety. PN-II, as it has been reported in [9], shows a high 
specificity toward pyrimidine nucleotides, being also able to 
dephosphorylate inosine and guanosine monophosphates, 
even though to a lesser extent. Since both PN-I and PN-II 
Table 1 
Purification of human erythrocyte PN enzymes 
Step PN-I 
Activity" (units) Spec. act. (U/mg) Yield (%) 
PN-II 
Activity11 (units) Spec. act. (U/mg) Yield (%) 
Lysate 
DEAE-cellulose 
Ammonium sulfate 
Phe-Seph. CL4B 
Hydroxyapatite 
TSK-DEAE 5PW 
TSK-Phe 5PW 
112 
54 
46.5 
19.3 
10.6 
4.9 
2.9 
0.00016 
0.0129 
0.0155 
0.0425 
0.960 
8.00 
28.2 
100 
48 
42 
17 
9.5 
4.3 
2.6 
259 
237 
245 
147 
102 
14.5 
13.6 
0.000371 
0.0564 
0.0817 
0.323 
9.27 
28.3 
73.9 
100 
91.5 
94.6 
56.8 
39.4 
5.6 
5.3 
"Activity was assayed by using 5'-CMP (PN-I) and 3'-UMP (PN-II) as the substrates. 
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hydrolyzed known antineoplastic agents, like 5'-AZTMP, 5'-
Ara-CMP, 5'-FdUMP, they might be expected to play a rel-
evant role in the metabolism of such pyrimidine analogues. 
Therefore the identification and/or rational design of effectors 
influencing PN-I and PN-II activity could be useful for the 
optimization of possible antineoplastic therapeutic protocols. 
Among a broad variety of compounds tested as hypothetical 
effectors of the nucleotidase activity, including inorganic 
phosphate, purine and pyrimidine bases, oxy- and deoxy-nu-
cleosides, mono-, di-, and triphosphates, dinucleoside poly-
phosphates, tiazofurin, theophylline, methylated uric acids, 
theobromine and caffeine, only the reaction products, i.e. 
the nucleoside and phosphate, resulted inhibitory. Further-
more, unlike other previously described soluble purine nucle-
otidases [22], PN-I and PN-II are not stimulated by ATP, 
ADP and 2,3-bisphosphoglycerate, thus ruling out a possible 
contamination of our preparation by the mentioned purine 
nucleotidase activities. Product inhibition studies on PN-II 
were carried out by using substrate 3'-UMP concentrations 
ranging from 0.1 to 1 mM, at different fixed concentrations of 
either phosphate (1-2 mM) or uridine (10-20 mM). Double 
reciprocal plots show that the inhibition exerted by phosphate 
appears to be competitive, with a K¡ value of 3.5 mM, as 
calculated from the slopes replot. The inhibition exerted by 
uridine is non-competitive of the mixed type and the inter-
cepts replot exhibits a non-linear pattern approaching to a 
plateau at high uridine concentration. Since the intercept rep-
resented the reciprocal of apparent maximal nucleotidase ac-
tivity, the plateau at high inhibitor concentration represents 
the residual activity of the inhibited enzyme. The data ob-
tained from the product inhibition experiments were consis-
tent with an ordered reaction, involving the release of nucleo-
side as the first product and of phosphate as the second [23]. 
3.4. PN-I and PN-II associated phosphotransferase activity 
3.4.1. Kinetic measurements. During the study of the in-
hibition exerted by different nucleosides on both PN-I and 
PN-II, by means of the HPLC-based assay, the appearance 
of the monophosphates of the nucleoside inhibitor was ob-
served in the elution pattern. In particular, when dThd was 
used as the inhibitor of PN-II, by using 3'-dUMP as the 
substrate, 3'-dTMP was formed. The production of 3'-
dTMP was depending upon the presence of 3'-dUMP in the 
incubation mixture and it was linearly time dependent (not 
250 
- . 200 - -
150 
100 -
o O 
50 -
20 40 
Time (min) 
Fig. 1. Time course of PN-I activities in the presence of 5'-CMP 
(250 uM), Urd (20 mM) and 10 mU/ml of pure PN-I under the as-
say conditions described in Section 2. (♦), 5'-CMP; (■), Cyd; (•), 
phosphate and ( A ) , UMP were determined. 
Fig. 2. Lineweaver-Burk plot of phosphotransferase activity of PN-
I. 5'-CMP and Urd were used as substrates. Urd phosphorylation 
was measured as described in Section 2 at different fixed concentra-
tions of Urd (mM): (o), 0.75; (•), 0.9; (0), 1.2; (♦), 2.0; ( A ) , 
3.75; ( A ) , 7.5; (D), 15; (■), 30. In the inset, slopes of interpolation 
lines are plotted against l/(Urd). 
shown) in the initial velocity conditions. This finding was 
consistent with a phosphotransferase activity associated with 
the PN-II enzyme protein, whereby the phosphate from the 
nucleoside monophosphate substrate was enzymatically trans-
ferred to the inhibitor nucleoside acceptor. Furthermore, an 
identical behaviour was observed for PN-I when it was incu-
bated with 5'-CMP and Urd, leading to the production of 5'-
UMP. To our knowledge the existence of nucleotidases en-
dowed with pyrimidine-specific phosphotransferase activity 
has never been described before. This observation appears 
of particular interest in view of the fact that several chemo-
therapeutic strategies are based on the use of pyrimidine ana-
logues, whose metabolic activation pathways may be pro-
foundly affected by the existence of such phosphotransferase 
activities. This prompted us to undertake an extensive study 
of the kinetic properties of the individual PN-I and PN-II 
enzyme activities, whose results could be exploited in the de-
signing of novel chemotherapeutic approaches as well as in 
the modulation of the existing ones. Fig. 1 shows the time 
course observed by incubating PN-I with 5'-CMP as the sub-
strate and Urd as the inhibitor/phosphate acceptor, leading to 
the formation of 5'-UMP. The same figure shows that upon 
prolonged incubation time, the newly formed 5'-UMP was 
hydrolyzed to Urd and inorganic phosphate after 40 min, 
whereas 5'-CMP was completely consumed after 30 min. As 
evidenced in Fig. 1, this resulted in a transient accumulation 
of 5'-UMP, the product of the phosphotransferase activity. 
Phosphotransferase activity was also detected by using stro-
ma-free hemolysate of fresh erythrocytes, as well as by using 
enzyme preparations at different degrees of purity. The frac-
tion of the transferred phosphate over the hydrolysed one was 
constant throughout all steps of the purification procedure 
(10% for PN-I, 7% for PN-II), thus suggesting that in human 
erythrocytes the pyrimidine nucleotidase and the pyrimidine 
phosphotransferase activities reside in the same protein. The 
examination of the Lineweaver-Burk plots of phosphotrans-
ferase activity showed converging patterns with respect to 
both donor and acceptor substrates (Figs. 2 and 3). The eval-
uation of the kinetic mechanism of phosphotransferase is not 
straightforward, since the enzymatic protein simultaneously 
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(Urd, mM)1 
Fig. 3. Lineweaver-Burk plot of phosphotransferase activity of PN-
I. 5'-CMP and Urd were used as substrates. Urd phosphorylation 
was measured as described in Section 2 at different fixed concentra-
tions of 5'-CMP (uM): (O), 5.0; (•), 6.25; (<>), 8.3; (♦), 12.5; 
( A ) , 25; ( A ) , 50; (D), 100; (■), 200. In the inset, slopes of interpo-
lation lines are plotted against l/(5'-CMP). 
catalyzes both the hydrolytic and phosphotransferasic reac-
tion. Indeed, due to the action of the intrinsic nucleotidase 
activity, this behaviour might be consistent both with an 
Ordered bi bi and a Ping-Pong kinetic mechanism, like it 
has been previously described for nucleoside phosphotransfer-
ase from barley [21]. In order to distinguish between the two 
mechanisms further experiments need to be done. In par-
ticular, experiments are in progress for the purpose of isolat-
ing a putative phosphoenzyme intermediate. Furthermore, 
from Figs. 2 and 3 plots, substrate inhibition was evidenced 
at high concentrations of the nucleoside acceptor, which was 
not abolished by increasing nucleotide concentrations (Fig. 3). 
From the same plots the kinetic constants of PN-I were 
calculated to be: is:m(5'-CMP) = 9 . 3 x l ( r 6 M, is:m(Urd) = 
6.4 XlO - 4 M, J£j(5'-CMP) = 8 . 7 x l ( r 6 M, ^¡(Urd) = 
3.0 XlCT3 M. 
3.4.2. Substrate specificity. In order to study the apparent 
specificity of PN-I and PN-II phosphotransferase activities, 
several nucleoside monophosphates were tested as donors to-
wards various nucleoside acceptors. The relative activity was 
calculated as the ratio of the nucleoside monophosphate 
formed by the phosphotransferase activity over the nucleoside 
liberated via the nucleotidase activity. The results are sum-
marized in Table 2. For PN-I the data show that the apparent 
specificity is principally influenced by the nucleoside acceptor, 
as evidenced by comparing the results obtained with a single 
acceptor (e.g. Cyd) with several donors, to those obtained 
with a single donor (e.g. 5'-CMP) with different acceptors; 
in this latter case a larger spreading of the apparent specific-
ities is observed by inspection of the data in Table 2. PN-I 
shows also a relatively low, but significant phosphotransferase 
activity toward AZT and AraC as the acceptors. Such an 
activity could play a relevant role both in the metabolism 
and in the pharmacokinetics of these important drugs. The 
phosphorylated product could be rapidly converted to the 
corresponding diphosphate by intracellular nucleotide kinase, 
widely distributed in human tissues, thus protecting it from 
the nucleotidase activity. PN-II phosphotransferase activity 
was most effective towards pyrimidine nucleoside 3'-mono-
phosphates leading to the production of nucleotides with the 
phosphate in the same position. In Table 2, the Km values for 
phosphotransferase activity possessed by PN-I and PN-II, to-
wards several substrates, are summarized. PN-I exhibited Km 
values for deoxy-nucleosides one order of magnitude higher 
than those for oxy-nucleosides, whereas the contrary appears 
to hold for PN-II. Furthermore, unlike other previously de-
scribed soluble purine nucleotidase/phosphotransferases [22], 
PN-I and PN-II phosphotransferase associated activities are 
not affected by ATP, ADP and 2,3-bisphosphoglycerate, thus 
ruling out the possibility that our pyrimidine nucleotidase 
preparations are contaminated by erythrocyte purine-specific 
nucleotidase/phosphotransferase activity. In addition, simi-
larly to the behaviour of the hydrolytic activities, the phos-
photransferase activities possessed by PN-I and PN-II are not 
influenced by other metabolites tested, including purine and 
pyrimidine bases, oxy- and deoxy-nucleoside mono-, di- and 
triphosphates, dinucleoside polyphosphates, tiazofurin, theo-
phylline, methylated uric acids, theobromine and caffeine. In 
our laboratory the search for an efficient modulator of both 
phosphotransferases is actively in progress. The interest on the 
possibility to modulate such metabolic pathways resides in 
their possible exploitation for the development of metabolic 
Table 2 
Phosphotransferase activity of PN-I and PN-II 
PN-I 
Donor (1 
CMP 
CMP 
CMP 
CMP 
CMP 
CMP 
CMP 
CMP 
UMP 
dCMP 
dUMP 
dTMP 
mM) Acceptor 
Urd 
dUrd 
dCyd 
dThd 
Ado 
AZT 
AraC 
5FdUrd 
Cyd 
Cyd 
Cyd 
Cyd 
(10 mM) Act. 
25 
1.5 
16 
0.5 
n.d.d 
1 
4 
n.d. 
36 
43 
15 
30 
(%)a Kmh 
0.64 
_ C 
7.4 
5.3 
-
-
0.79 
-
-
-
PN-II 
Donor (1 mM) 
3'-UMP 
3'-dUMP 
3'-dUMP 
3'-dUMP 
3'-dUMP 
3'-dUMP 
3'-dUMP 
3'-dUMP 
3'-dUMP 
3'-dUMP 
3'-dUMP 
3'-dUMP 
Acceptor 
dUrd 
dThd 
Urd 
Cyd 
dCyd 
Ado 
dAdo 
Ino 
sino 
AZT 
AraC 
5FdUrd 
(10 mM) Act. 
29 
16.8 
2 
n.d.d 
n.d. 
n.d. 
n.d. 
n.d. 
n.d. 
n.d. 
n.d. 
19.7 
(%)a Kmh 
6 
12.3 
>100 
7.6 
Percentage of phosphate transferred from nucleoside monophosphate donor to nucleoside acceptor. 
hKm of acceptor, values in mM. cNot determined. 
dNot detectable. 
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engineering-based antineoplastic and antiviral therapeutic 
strategies. 
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